紫龙金片联合化疗对晚期肺癌的临床疗效  

Clinical efficacy of Zilongjin Tablets combined with chemotherapy in advanced lung cancer

作　　者：马惠文[1] 方骏 王思雄[1] 王东林[1] 王婷[1] 王恩文[1] 

机构地区：[1]重庆市肿瘤研究所/重庆市肿瘤医院/重庆市癌症中心肿瘤内科,400030 [2]重庆康华众联心血管病医院心外一科,400023

出　　处：《检验医学与临床》2017年第22期3318-3320,共3页Laboratory Medicine and Clinic

基　　金：重庆市科技惠民计划资助项目(cstc2015jcsf10007-2)

摘　　要：目的研究紫龙金片联合化疗对晚期肺癌的临床疗效与不良反应。方法选取收治的78例晚期肺癌患者,按随机双盲法分为联合组(39例)与对照组(39例),联合组患者接受吉西他滨加顺铂(GP)方案联合紫龙金片治疗,对照组患者接受GP方案联合安慰剂治疗。在连续接受2个周期治疗后,分别监测与对比各组患者的客观有效率、生命质量、免疫功能变化及不良反应发生情况。结果联合组与对照组的客观有效率分别为43.6%、38.5%,差异无统计学意义(P>0.05);2组控制率分别为82.1%、64.1%,差异有统计学意义(P<0.05);2组生命质量提高例数分别为19例、15例,差异有统计学意义(P<0.05);治疗后联合组CD4与CD4/CD8变化均优于对照组,差异有统计学意义(P<0.05);不良反应发生率方面,联合组较对照组有明显优势。结论晚期肺癌化疗方案中联合使用紫龙金片,可在提升疗效的同时改善患者的生命质量,降低化疗不良反应的发生率,其机制或与紫龙金片抗肿瘤作用及调节免疫功能相关。ObjectiveTo investigate the clinical efficacy and adverse reactions of Zilongjin Tablets combined with chemotherapy in the patients with advanced lung cancer.MethodsSeventy eight cases of advanced lung cancer treated in this hospital were selected and divided into the combined group（39 cases）and control group（39 cases）according to the random double blind method.The combined group received the regimen（GP）of gemcitabine plus cisplatinum combined Zilongjin Tablets,while the control group received the GP regimen combined with placebo treatment.After 2 consecutive cycles of treatment,the objective effective rate,quality of life,changes of immune function and adverse reactions were monitored and compared between the two groups.ResultsThe objective effective rates in the combined group and control group were 43.6% and 38.5% respectively,there was no statistically significant difference between the two groups（P〉0.05）;the control rates in the two groups were 82.1% and 64.1% respectively,there was statistically significant difference（P〈0.05）;the cases of living quality improvement in the two groups were 19 cases and 15 cases,the difference between the two groups was statistically significant（P〈0.05）;the CD4 and CD4/CD8 changes in the combined group were better than those in the control group,the difference was statistically significant（P〈0.05）;the combined group had the advantages in the aspect of adverse reaction occurrence rate than the control group.ConclusionThe combined use of Zilongjin Tablets in the chemotherapeutic regimens of advanced lung cancer can improve the curative effect,meanwhile can improve the quality of life of patients and reduces the incidence rate of chemotherapy adverse reactions,its mechanism may be related with the anti tumor effect and immune regulation function of Zilongjin Tablets.

关 键 词：晚期 非小细胞肺癌 紫龙金 联合化疗 

分 类 号：R286.91[医药卫生—中药学]